Member Info for Fruitsnveg

"What kind of reaction is there in the BP world, on whom we are totally dependent, when a known "voice" like Brooke Clarke is allowed to leave"

lol.

I think you are conflating current circumstances with an overly-dramatic episode of Neighbours circa 1997.

You haven't noticed it TP...?

It would be nice but I don't see the value in vague updates, particularly with the SP so open to abusive manoeuvres. The less they say the better until there is something very concrete to report. They are under no obligation to provide operational updates in the meantime, although I suppose one could view latest email response (see below) as ticking that box:

"Many thanks for your recent enquiry. Synairgen is progressing its plans, based on insights from non-interventional studies, to assess SNG001 in target patient groups with the highest needs. You can expect announcements when substantive milestones are reached, and as per the financial calendar, with full year results for 2023 due to be reported in Q2."

I feel a bit late to the party on this one (proof if ever it was needed that I am not in fact RM or one of his minions, lol!).

Anyway, you can look at this covert hire a number of ways, I find all of these to be positive to getting us where we need to be. It is:

- a sign of growth and expansion - self explanatory what is coming, i.e. growth and expansion!....

- a sign that funds will need to be raised - a financial controller can provide accurate financial data to potential investors

- a sign that trials are surely coming, perhaps rubber stamped now by some regulatory green flag? Financial controllers play a critical role in managing budgets for clinical trials because they track expenses related to research, development, and regulatory compliance.

- A sign of due diligence on the horizon. When mergers, acquisitions, or licensing agreements are being considered, a financial controller ensures thorough due diligence in the process.

- A financial controller ensures compliance with financial regulations, (local) tax laws, and reporting requirements, particularly important when scaling up with a foreign element...

We don't know which of these applies here, but what is clear is that hiring a financial controller should always align with a company’s growth stage, financial needs, and strategic goals. This hire in November 23 is an indication IMO that we are without doubt moving to the next level.

Nobody "lost" anything. Funds get 'spent''.

And just to add, there was no mystery in John Ward's departure:

"owing nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO and Executive Director on Friday 3 November.

Richard Marsden, CEO of Synairgen, said: "Joseph's many years of listed company experience, including in the healthcare sector, will stand us in good stead as we progress towards the clinic with our SNG001 strategy. I'd like to thank John for his steadfast commitment, loyalty and support to both me and the Board over many years. We wish him the very best for the future." Joseph Colliver, newly appointed CFO of Synairgen, commented: "This is a pivotal time for the Company, as it works towards the next phase of clinical trials with SNG001. I look forward to working closely with Richard and the team in the coming months and years." John Ward, outgoing CFO of Synairgen, commented: "It has been a pleasure to work with the Synairgen team for these many years, driven by the shared vision to develop treatments for severe viral lung infections. However, it's the right time to pass on the baton, and I look forward to following the Company's next steps and wish the team every success with SNG001 in the future."

Still, your fictional version of events was entertaining, if not wholly expected Ms. Mani.

"The strategic plan is to get the P2s done as well as possible - see what that does to the share value of the company - and decide on the best P3 partner from that position."

No where in the Annual Report is that strategic plan articulated thus. Made up nonsense. READ THE REPORT.

They have advisors. And they have a plan. Those are articulated there. Page 5 of the last annual report.

It's only a loss when you sell.

Repeat after me Prof, .....

"Lets talk what the obligations are for our management. Legally and morally. And are the adhering to both?".

As you know, there are no provisions in the regulations to uphold moral values. On the legal front, my advisor seems to think so and unequivocally, so do I. I suggest you tell us clearly here how you feel the company are falling short on their legal responsibilities? Please refer directly to which statutory obligations you think are not being met, rather than your loose interpretation of these...

I second this. Anyone who needs reminding of the market abuse regulations, and persists with flouting them here, take fair warning from the definitions provided today. They are there to PROTECT genuine shareholders, albeit a minority of posters here.

As for joining in some joint action initiated by Spacdan? I'd sooner stick onions in my ears than trust the motives of said poster.

Timeo Danaos et dona ferentes.

That's guff Doc.Dan. You've firmly aligned yourself with the bottom feeders here, defending them ad nauseum even long they outed themselves as SP destroyers that they are. They don't give a tos$ about the company or the drug or the patients who will benefit from it. You can't be a genuinely invested PI AND defend the self-confessed shorters and day traders whose sole aim here is to destroy shareholder confidence. That's where your strategy falls well short, forgive the pun.

I think that's fair, and realistic.

I'm no longer here to do your research Doc.Dan. I dislike your denial of the facts, and your increasingly rude tone to others who are simply here to add to the conversation, so I'm not sure why you think I would want to waste my time providing you with more evidence. We know after 3 years of this charade that you will readily dismiss the facts without a backwards glance. It does not surprise me that you don't remember them. You appear to have very selective recall these days. Anyway, as I said before, it's high time you shoved Mani aside and took control of that Olivetti, re-bob the ribbon, put some diesel in it, and let rip on google. There's plenty of available info on trials and studies being run, all add to greater understanding. I would be very surprised if these aren't informing Synairgen in progressing.

That is why I am happy to wait, knowing a CMO has been hired to push forwards into another, as yet unseen, phase.

No smoke without fire, etc etc.

"anything useful UNIVERSAL throws up". As if it will be some incidental, inconsequential and haphazard bit of nothing data that might elevate the existing mountain of nothing, is that what you are inferring Doc.Dan? Because is sure does seem to be. As always you are screaming for more, yet master of downplaying every positive step the company take. The foolery is not lost. And no, it won't be "in the way" you outlined. It will, with any luck, be much more substantial, critical and and useful to BP, or any other interested parties despite your best efforts here to convince otherwise.

MyIPA, that is incorrect. There have been new findings, relevant respiratory studies done not just abroad but in this country too. Some are still being done. All information available publicly if you dig. The specific costings (end points of Universal) also were not known before it started, but they will be now. Also DO NOT underestimate the data from an observational study. Although randomised controlled trials are the gold standard for evaluating treatment efficacy in patients, due to strict inclusion criteria and conditions required for ascertaining statistical significance, the % of patients included typically represent as little as 5% of the disease population. Therefore observational studies like Universal, because it's focussed on broader patient populations entering hospital with a myriad of medical and respiratory issues, are becoming increasingly important. There is a lot of data that is of interest to BP even from observational studies. That is why they do them. It's not to pass time or for fun. You said "They won't add much to what we already know"; if by "we" you mean Doc.Dan and his cohort, then you are correct. There's not much any of them wish to know because it's not in their interests to seek out the facts.

I encouraged DocDan to do his own research on the current studies happening in NIHR sites around the UK which Synairgen will be interested in for trial design purposes, but the old guffer wasn't up to the task, or couldn't prise Mani's cold claws off the Olivetti. Whichever it was, willful ignorance garners no support nor sympathy here.

The negative trollfest is in part to dissuade further PIs entering here. Nothing to see here. A good sign that there IS something to see here, when it's ready to be revealed, no? But I'm sure you've worked that out already Ghia.

"UNIVERSAL will add its findings, but they won't be much different to what we already know"; that's a willfully misleading statement, and you know it Doc.Dan.

And you also know, or should, that the company are evidencing multiple studies. Universal is but one.

A for effort, D for execution.

As a reminder, this was the September update to shareholders from the company:

Operational

· Progressing the Company's patient identification strategy through biomarker and existing clinical data analysis. This will enable the Company to identify patients at higher risk of disease progression, including those with deficient innate immune response and/or high viral load, who might therefore be more likely to respond to SNG001 in future clinical studies.

· Conducting non-interventional preparatory work to expand hospitalised patient populations for potential treatment with SNG001, which are likely to include: ventilated patients with confirmed viral pneumonia; and patients who are unable to clear virus and become persistent viral "shedders", a majority of whom are immunocompromised. Subject to this preparatory work and regulatory approval timelines, trials are anticipated to start in H1 2024.

· Insights from non-interventional studies and the substantial body of evidence gathered to date from previous clinical trials will inform a robust clinical programme for the development of SNG001.

I would expect to have another update form the company by March, maybe sooner. As I have sad previously, the work of the newly hired CMO is at a critical now, as is the cooperation of the Regulators. The vast swathe of critical pre-trial and pre-launch activities, often being done with other parties, should not be underestimated. Anyone who thinks this is a cake-walk phase that takes a just a few meetings and not much else, should not be invested here, IMO. Those of us who invested with this knowledge, are not perturbed by the silence or the timeframes required.